Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450359 | 0.86 | DRD4 (0.46) | SCN4ADRD2DRD4DRD3KCNH2 | |
| SCHEMBL6538591 | 0.85 | KCNA3 (0.41) | DRD2DRD4DRD3KCNH2TAAR1 | |
| SCHEMBL7862622 | 0.83 | DRD2 (0.47) | DRD2DRD4DRD3KCNH2 | |
| SCHEMBL1532027 | 0.78 | MAOA (0.42) | L3MBTL1MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1907545 | 0.77 | MAOB (0.43) | L3MBTL1MAOBAPPNPC1RAB9A | |
| SCHEMBL4314683 | 0.77 | DRD2 (0.58) | SCN4ADRD2DRD4DRD3KCNH2 | |
| SCHEMBL1003652 | 0.77 | MAOB (0.50) | SCN4ADRD2DRD4DRD3KCNH2 | |
| SCHEMBL9031404 | 0.77 | — | — | |
| SCHEMBL2150076 | 0.75 | — | — | |
| SCHEMBL4827804 | 0.75 | GPR84 (0.47) | TAAR1MAOBNPC1RAB9AGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | SCN4A 1736/4885DRD2 409/4885DRD4 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.